{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:24:32Z","timestamp":1746339872933},"reference-count":22,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2010,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1111\/j.1365-2354.2008.01004.x","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T09:44:29Z","timestamp":1245663869000},"page":"200-204","source":"Crossref","is-referenced-by-count":9,"title":["Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel\/epidoxorubicin\/cyclophosphamide"],"prefix":"10.1155","volume":"19","author":[{"given":"L.","family":"MONTELLA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"ADDEO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"GUARRASI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"CENNAMO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"FAIOLA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"CAPASSO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"CARAGLIA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. DEL","family":"PRETE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","article-title":"30 years\u2019 follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study","volume":"330","author":"Bonadonna","year":"2005","journal-title":"British Medical Journal"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB2","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1111\/j.1365-2354.2008.01004.x-BIB3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0093-7754(03)00314-2","article-title":"Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia","volume":"30","author":"Crawford","year":"2003","journal-title":"Seminars in Oncology"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/oxfordjournals.annonc.a010544","article-title":"A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer. A report of the Clinical Screening Group of the EORTC","volume":"7","author":"Fumoleau","year":"1996","journal-title":"Annals of Oncology"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB6","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Kearney","year":"2006","journal-title":"European Journal of Cancer"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB7","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.6004\/jnccn.2005.0031","article-title":"Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence","volume":"3","author":"Lyman","year":"2005","journal-title":"The Journal of the National Comprehensive Cancer Network"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB10","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/annonc\/mdl135","article-title":"Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen","volume":"17","author":"Martin","year":"2006","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1111\/j.1365-2354.2008.01004.x-BIB11","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1592\/phco.23.9.3S.32886","article-title":"Pegylation: engineering improved biopharmaceuticals for oncology","volume":"23","author":"Molineux","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/1381612043452613","article-title":"The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta)","volume":"10","author":"Molineux","year":"2004","journal-title":"Current Pharmaceutical Design"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","article-title":"Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices","volume":"13","author":"Morrison","year":"2007","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2001.19.2.314","article-title":"Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer","volume":"19","author":"Nabholtz","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1634\/theoncologist.12-4-484","article-title":"Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use","volume":"12","author":"Ozer","year":"2007","journal-title":"The Oncologist"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB16","first-page":"16","article-title":"Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits","volume":"20","author":"Rader","year":"2006","journal-title":"Oncology"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB17","first-page":"715","article-title":"A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer","volume":"10","author":"Siena","year":"2003","journal-title":"Oncology Reports"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3816\/CBC.2002.n.036","article-title":"Phase II trial of doxorubicin\/docetaxel\/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58","volume":"3","author":"Smith","year":"2002","journal-title":"Clinical Breast Cancer"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB19","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"Recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB20","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1111\/j.1365-2354.2008.01004.x-BIB21","article-title":"Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel\/doxorubicin\/cyclophosphamide (TAC) in breast cancer patients","volume":"23","author":"Von Minckwitz","year":"2005","journal-title":"Journal of Clinical Oncology, ASCO Annual Meeting Proceedings"},{"key":"10.1111\/j.1365-2354.2008.01004.x-BIB22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","article-title":"Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma","volume":"21","author":"Vose","year":"2003","journal-title":"Journal of Clinical Oncology"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2354.2008.01004.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2354.2008.01004.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:09:52Z","timestamp":1671541792000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2354.2008.01004.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2354.2008.01004.x","relation":{},"ISSN":["0961-5423","1365-2354"],"issn-type":[{"value":"0961-5423","type":"print"},{"value":"1365-2354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}